

ANIMAL MODELS IN PRECLINICAL STUDIES FOR ANTIFERTILITY

B. V. Gokul Bal*, Dr. R. Manivannan, M. Bhuvanesh, M. Damodaran, P. Dharani
Priya, S. Dhinesh Kumar

Department of Pharmacology, Excel College of Pharmacy, Komarapalayam, Namakkal Dt.
Tamil Nadu, India.

Article Received on 15 Feb. 2026,
Article Revised on 05 March 2026,
Article Published on 16 March 2026,

<https://doi.org/10.5281/zenodo.19081634>

*Corresponding Author

B. V. Gokul Bal

Department of Pharmacology, Excel
College of Pharmacy,
Komarapalayam, Namakkal Dt.
Tamil Nadu, India.



How to cite this Article: B. V. Gokul Bal*, Dr. R. Manivannan, M. Bhuvanesh, M. Damodaran, P. Dharani Priya, S. Dhinesh Kumar. (2026). Animal Model In Perclinical Research For Anti Cancer. World Journal of Pharmaceutical Research, 15(6), 1309-1317.

This work is licensed under Creative Commons Attribution 4.0 International license.

ABSTRACT

- Preclinical research is a crucial step in the development of antifertility drugs and modern contraceptive technologies. Before any new compound is introduced into human trials, it must be carefully tested in animal models to evaluate its safety, effectiveness, pharmacokinetic behavior, pharmacodynamic effects, and potential reproductive toxicity. Animal species such as rodents, rabbits, and nonhuman primates are commonly used because they mimic several aspects of human reproductive physiology.
- Through these models, researchers can study key reproductive processes including ovulation, spermatogenesis, hormonal balance, implantation, and overall reproductive safety. Although animal models cannot completely replicate human reproductive biology, they remain essential for regulatory approval and for ensuring that new contraceptive agents are both safe and effective.

This review discusses the basic concepts of fertility and antifertility, the importance of research in this area, classification of antifertility agents, commonly used animal models, anti-implantation and hormonal evaluation methods, and the advantages and limitations of these experimental systems in contraceptive research.

- **KEYWORDS:** Antifertility, Preclinical studies, Animal models, Contraception, Anti-implantation, Hormonal evaluation.

INTRODUCTION

Preclinical studies form the backbone of antifertility drug development. They serve as an essential link between laboratory discoveries and human clinical trials by allowing researchers to assess biological activity, safety, and mechanisms of action within a complete living system.

Animal models are widely used to simulate reproductive functions and to investigate:

- Suppression of ovulation
- Inhibition of spermatogenesis
- Modulation of reproductive hormones
- Prevention of implantation
- Reproductive toxicity

Rodents are typically chosen for early screening studies because of their short reproductive cycles, rapid breeding, and affordability. Rabbits are often used as non-rodent models, particularly for embryo-fetal toxicity and vaginal contraceptive testing. Nonhuman primates are employed in advanced stages of research due to their closer resemblance to human reproductive physiology.

CONCEPT OF FERTILITY

Fertility is the natural biological ability to reproduce and achieve a successful pregnancy.

It depends on several well-coordinated processes, including:

- Gamete formation (gametogenesis)
- Ovulation
- Fertilization
- Implantation of the embryo
- Maintenance of pregnancy

Clinically, infertility is defined as the inability to conceive after one year of regular, unprotected intercourse.

CONCEPT OF ANTIFERTILITY

Antifertility refers to the ability of a substance or method to reduce, suppress, or prevent fertility.

These agents may act through various mechanisms, such as:

- Preventing ovulation
- Suppressing sperm production
- Altering hormonal balance
- Blocking fertilization
- Inhibiting implantation

Before such agents can be used in humans, thorough preclinical testing in animal models is required to confirm their safety and effectiveness.

NEED FOR ANTIFERTILITY RESEARCH

1. Public Health Importance

A large number of women worldwide still lack access to reliable contraception, leading to unintended pregnancies and associated health risks. Continued research in antifertility methods helps address this global public health challenge.

2. Reduction of Maternal and Infant Mortality

Effective contraception plays a significant role in reducing unsafe abortions, maternal complications, and infant mortality, thereby improving overall family health.

3. Limitations of Current Contraceptives

Although current hormonal contraceptives are effective, they may produce side effects such as:

- Weight changes
- Mood disturbances
- Hormonal imbalance

As a result, ongoing research focuses on developing safer, reversible, and preferably non-hormonal contraceptive options.

4. Regulatory Requirements

Regulatory authorities require detailed reproductive toxicity data from animal studies before granting approval for human clinical trials.

ROLE OF PRECLINICAL STUDIES

Preclinical studies are designed to:

1. Assess Safety

Identify potential reproductive and systemic toxic effects.

2. Evaluate Efficacy

Demonstrate the ability of a compound to prevent pregnancy in suitable animal models.

3. Study Pharmacokinetics

Analyze how the drug is absorbed, distributed, metabolized, and eliminated from the body.

4. Study Pharmacodynamics

Examine the biological effects of the drug on reproductive hormones and target tissues.

5. Determine Safe Starting Dose

Establish the maximum tolerated dose to guide the initial dosing in human trials.

SELECTION OF EXPERIMENTAL ANIMALS

The selection of appropriate animal models depends on:

- Similarity of physiology to humans
- Characteristics of the reproductive cycle
- Availability of background scientific data
- Ethical considerations

1. Rodents (Rats and Mice)

Rats and mice are widely used due to their:

- Short estrous cycles
- Large litter sizes
- Low maintenance cost
- Suitability for hormonal and mechanistic studies

2. Rabbits

Rabbits serve as important non-rodent models, particularly in embryo-fetal toxicity studies and vaginal contraceptive research.

3. Nonhuman Primates

Nonhuman primates closely resemble human reproductive physiology. They are primarily used in advanced translational research but involve higher costs and ethical sensitivity.

CLASSIFICATION OF ANTIFERTILITY AGENTS

1. Hormonal Agents

- Combined oral contraceptives
- Progestin-only preparations
- Injectable contraceptives
- Hormone-releasing intrauterine systems

2. Non-Hormonal Agents

- Barrier methods
- Copper intrauterine devices
- Spermicides
- Investigational small-molecule agents

3. Male Antifertility Agents

- Hormonal suppression of spermatogenesis
- Non-hormonal agents targeting sperm production or function

MALE ANTIFERTILITY ANIMAL MODELS

1. Rodent Models

Rodent models are used to evaluate

- Sperm count
- Sperm motility
- Testicular histopathology
- Reversibility of fertility
- Genetically modified mice are particularly valuable for identifying molecular pathways involved in fertility regulation.

2. Nonhuman Primate Models

These models are utilized for

- Hormonal suppression studies
- Testing contraceptive devices involving the vas deferens

- Behavioral fertility assessments

FEMALE ANTIFERTILITY ANIMAL MODELS

1. Female Rat Model

Used to evaluate

- Anti-ovulatory activity
- Anti-implantation effects
- Hormonal alterations

2. Female Rabbit Model

Commonly employed for

- Vaginal contraceptive testing
- Spermicidal activity assessment
- Reproductive toxicity evaluation

3. Nonhuman Primate Model

Applied in

- Hormonal contraceptive testing
- Device evaluation
- Advanced translational reproductive studies

ANTI-IMPLANTATION MODELS

1. Rat Anti-implantation Model

The standard procedure involves:

- Confirming mating through vaginal smear examination
- Administering the test compound during early gestation
- Examining and counting uterine implantation sites
- A decrease in implantation sites indicates antifertility activity

2. Hormonal Anti-implantation

Agents such as antiprogestins and antiestrogens prevent implantation by altering endometrial receptivity.

HORMONAL EVALUATION PARAMETERS

The main reproductive hormones measured include:

- Follicle Stimulating Hormone (FSH)
- Luteinizing Hormone (LH)
- Estradiol
- Progesterone

Common laboratory methods used are

- Enzyme-Linked Immunosorbent Assay (ELISA)
- Radioimmunoassay (RIA)

These assessments help evaluate disturbances in the hypothalamic–pituitary–gonadal axis.

ADVANTAGES OF ANIMAL MODELS

- Controlled experimental settings
- Better understanding of mechanisms
- Reliable safety evaluation
- Cost-effective preliminary screening
- Ethical safeguard before human exposure

LIMITATIONS OF ANIMAL MODELS

- Physiological differences between species
- Limited direct translation to human outcomes
- Ethical concerns
- Difficulty in dose extrapolation
- Shorter reproductive cycles compared to humans

CONCLUSION

- Animal models continue to play a critical role in the development of antifertility drugs and contraceptive technologies. They provide essential information on safety, efficacy, hormonal regulation, implantation processes, and reproductive toxicity before human testing begins. Rodents are primarily used for early screening, rabbits serve as important non-rodent models, and nonhuman primates are reserved for advanced translational studies.

- Despite certain limitations, adherence to ethical guidelines and scientific rigor ensures responsible research. Ongoing improvements in experimental models will support the development of safer, more effective, and reversible contraceptive methods in the future.

REFERENCES

1. Rang & Dale's Pharmacology. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. London: Elsevier, 2020.
2. Goodman & Gilman's The Pharmacological Basis of Therapeutics. Brunton LL, Hilal-Dandan R, Knollmann BC. The Pharmacological Basis of Therapeutics. 13th ed. New York: McGraw-Hill, 2018.
3. Wilson and Gisvold's Textbook of Organic Medicinal and Pharmaceutical Chemistry. Beale JM, Block JH. Wilson and Gisvold's Textbook of Organic Medicinal and Pharmaceutical Chemistry. 12th ed. Philadelphia: Lippincott Williams & Wilkins, 2011.
4. World Health Organization. WHO. Medical Eligibility Criteria for Contraceptive Use. Geneva: WHO Press, 2015.
5. Organisation for Economic Co-operation and Development. OECD. Guidelines for the Testing of Chemicals: Reproductive Toxicity Studies. Paris: OECD Publishing, 2018.
6. U.S. Food and Drug Administration. FDA. Guidance for Industry: Reproductive and Developmental Toxicities. Silver Spring, MD, 2020.
7. Choudhary DN, Singh JN. Antifertility effects of medicinal plants: A review. International Journal of Pharmaceutical Sciences Review and Research, 2015; 30(1): 12-18.
8. Vogel HG, Vogel WH. Drug Discovery and Evaluation: Pharmacological Assays. 3rd ed. Berlin: Springer, 2008.
9. Turner PV, Brabb T, Pekow C, Vasbinder MA. Administration of substances to laboratory animals: Routes and techniques. Journal of the American Association for Laboratory Animal Science, 2011; 50(5): 600-613.
10. Saito K, et al. Animal models in reproductive toxicology studies. Reproductive Toxicology, 2016; 56: 1-10.
11. Khanna U, Chaudhury RR. Antifertility screening of plants: Methods and approaches. Indian Journal of Experimental Biology, 1968; 6: 252-262.
12. Setty BS, Kar AB. Studies on antifertility activity of compounds using rat models. Indian Journal of Medical Research, 1970; 58: 1158-1166.
13. Anderson RA, Baird DT. Male contraception. Endocrine Reviews, 2002; 23(6): 735-762.

14. Kumar D, Kumar A, Prakash O. Potential antifertility agents from plants: A comprehensive review. *Journal of Ethnopharmacology*, 2012; 140(1): 1-32.
15. Gupta RS, Sharma R. Evaluation of antifertility effects in experimental animal models. *Asian Journal of Pharmaceutical and Clinical Research*, 2013; 6(3): 7-12.